Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
498.60    -0.80 (-0.16%)
Bid:
498.20
Ask:
498.80
Spread: 0.60 (0.12%)
Market Cap: £1.35b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Contract Awards

11 Sep 2019 07:00

RNS Number : 8876L
Chemring Group PLC
11 September 2019
Β 

FOR IMMEDIATE RELEASE 11 SEPTEMBER 2019

Β 

CHEMRING GROUP PLC ("Chemring", the "Group" or the "Company")

Β 

CONTRACT AWARDS

Β 

Β 

Chemring Group is pleased to announce that its US based subsidiary, Chemring CountermeasuresΒ USA ("CCM USA"), has been awarded four contracts to supply countermeasures in support of the US Navy and US Air Force.

Β 

The first contract, which is for the manufacture and delivery of MJU-64/B infrared decoys for the US Navy, is valued at $4.2 million, and was awarded to CCM USA with a second year award option in 2020. Deliveries under this contract will be made in 2019, with all work to be performed at CCM USA's facility in Chester Township, Pennsylvania.Β 

Β 

The second contract is an $8.1 million delivery order against an existing $94 million three year Indefinite Delivery/Indefinite Quantity (IDIQ) contract, which is for the manufacture and delivery of MJU-66 flares for the US Navy and US Air Force. Deliveries under this contract will be made in 2020, with all work to be performed at CCM USA's facility in Chester Township, Pennsylvania.Β 

Β 

The third contract is a three year IDIQ contract for the manufacture and delivery of MJU-53/B flares for the US Air Force, with a maximum value of $90 million. The first delivery order against this contract is expected shortly with deliveries being made in 2020. Deliveries under this IDIQ are expected to be completed by July 2023, with all work being performed at CCM USA's facility in Toone, Tennessee.

Β 

The fourth contract is a five year IDIQ for manufacture and delivery of the MJU-52A/B BOL IR flare for the US Air Force F-15 ANG, with a maximum value of $25 million. The first delivery order against this contract is for $5.2 million with deliveries being made in 2020. All work under this contract will be performed at CCM USA's facility in Chester Township, Pennsylvania.

Β 

Mick Ord, Group Chief Executive of Chemring, commented:

Β 

"These contracts demonstrate the continued confidence of the US Navy and Air Force in Chemring's ability to develop and supply quality aircraft countermeasures, and it recognises our dedication to protecting our customers.

Β 

"These contracts also complete the required FY19 order intake in our Countermeasures segment and provide a strong platform for FY20. They are further evidence of the recovery, and our strengthening position, in the global countermeasures market and supports the Group's investment in its facilities."

Β 

-ENDS-

Β 

Β 

For further information:

Β 

Rupert Pittman Group Director of Corporate Affairs, 01794 833901

Chemring Group PLC

Β 

Andrew Jaques MHP Communications 020 3128 8100

Oliver Hughes

Β 

Notes to editors

Β·; Chemring is a global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

Β·; Employing approximately 2,500 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

Β·; Chemring is organised under three strategic product segments: Countermeasures, Sensors, and Energetics

Β·; Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

Β·; Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

Β 

www.chemring.co.uk

Β 

Cautionary statements

This announcement contains unaudited information based on management accounts and forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements.

Β 

There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are; increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects.

Β 

Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

Β 

No statement in this announcement is intended as a profit forecast for FY19 and no statement in this announcement should be interpreted to mean that underlying operating profit for the current or future financial years would necessarily be above a minimum level, or match or exceed the historical published underlying operating profit or set a minimum level of underlying operating profit.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
NRASFMFMSFUSEIU
Date   Source Headline
3rd Jun 20264:00 pmRNSHolding(s) in Company
2nd Jun 20267:02 amRNSDirectorate change
2nd Jun 20267:00 amRNSInterim results
1st Jun 20267:00 amRNSTotal Voting Rights
28th May 20262:36 pmRNSHolding(s) in Company
22nd May 20269:15 amRNSHolding(s) in Company
21st May 20267:00 amRNSHolding(s) in Company
14th May 20267:00 amRNSHolding(s) in Company
1st May 20267:00 amRNSHolding(s) in Company
1st May 20267:00 amRNSTotal Voting Rights
1st Apr 20267:00 amRNSTotal Voting Rights
31st Mar 20263:46 pmRNSDirector/PDMR Shareholding
19th Mar 202611:00 amRNSHolding(s) in Company
4th Mar 20267:00 amRNSAppointment of non-executive director
2nd Mar 20269:15 amRNSTotal Voting Rights
20th Feb 20262:48 pmRNSResult of AGM
20th Feb 20267:00 amRNSAGM Update
16th Feb 20267:00 amRNSHolding(s) in Company
9th Feb 20267:00 amRNSHolding(s) in Company
2nd Feb 20267:00 amRNSTotal Voting Rights
23rd Jan 20264:41 pmRNSDirector/PDMR Shareholding
12th Jan 20261:35 pmRNSNotice of AGM
2nd Jan 202610:29 amRNSTotal Voting Rights
19th Dec 202511:53 amRNSHolding(s) in Company
19th Dec 202511:53 amRNSHolding(s) in Company
18th Dec 20257:00 amRNSBlock listing Interim Review
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
15th Dec 20258:42 amRNSTransaction in Own Shares
12th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20253:01 pmRNSAdditional Listing - Replacement
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 202512:41 pmRNSDirector/PDMR Shareholding
10th Dec 202512:40 pmRNSDirector/PDMR Shareholding
10th Dec 202512:40 pmRNSDirector/PDMR Shareholding
10th Dec 202512:38 pmRNSDirector/PDMR Shareholding
10th Dec 202512:36 pmRNSDirector/PDMR Shareholding
10th Dec 202512:36 pmRNSDirector/PDMR Shareholding
10th Dec 20257:00 amRNSAdditional Listing
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20254:23 pmRNSDirector/PDMR Shareholding
9th Dec 20257:00 amRNSResults for the year ended 31 October 2025
9th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
5th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.